asp9521
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT01352208)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
AKR1C3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 1-(1-((5-methoxy-1h-indol-2-yl)carbonyl)piperidin-4-yl)-2-methylpropan-2-ol
- asp9521
- asp9521
- asp9521
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01352208 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2011 | Astellas |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 1 | 1 | 1 | 2011 |
1 organizations
Page 1 / 1